Verzenio/Verzenios (abemaciclib) vs Phesgo (pertuzumab, trastuzumab, and hyaluronidase)
Verzenio/Verzenios (abemaciclib) vs Phesgo (pertuzumab, trastuzumab, and hyaluronidase)
Verzenio (abemaciclib) is a CDK4/6 inhibitor used primarily for the treatment of certain types of hormone receptor-positive, HER2-negative breast cancer, often in combination with an aromatase inhibitor or fulvestrant. Phesgo is a combination of two monoclonal antibodies, pertuzumab and trastuzumab, with hyaluronidase, and is used for the treatment of HER2-positive breast cancer, administered subcutaneously to target and inhibit the HER2 protein's activity. The choice between Verzenio and Phesgo would depend on the specific subtype of breast cancer a patient has, as Verzenio is not suitable for HER2-positive breast cancer, while Phesgo is specifically designed for it, and their respective treatment regimens should be determined by a healthcare professional based on the patient's individual medical condition and history.
Difference between Verzenio/Verzenios and Phesgo
Metric | Verzenio/Verzenios (abemaciclib) | Phesgo (pertuzumab, trastuzumab, and hyaluronidase) |
---|---|---|
Generic name | Abemaciclib | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf |
Indications | HR-positive, HER2-negative advanced or metastatic breast cancer | HER2-positive breast cancer |
Mechanism of action | CDK4 & CDK6 inhibitor | HER2 inhibitor, monoclonal antibodies |
Brand names | Verzenio, Verzenios | Phesgo |
Administrative route | Oral | Subcutaneous injection |
Side effects | Diarrhea, neutropenia, nausea, abdominal pain | Fatigue, alopecia, nausea, diarrhea |
Contraindications | Liver impairment, pregnancy | Known hypersensitivity to active substances or excipients |
Drug class | Antineoplastic agents, kinase inhibitors | Antineoplastic agents, monoclonal antibodies |
Manufacturer | Eli Lilly and Company | Genentech, Inc. |
Efficacy
Verzenio (Abemaciclib) Efficacy in Breast Cancer
Verzenio, known generically as abemaciclib, is a targeted therapy approved for the treatment of certain types of breast cancer. Specifically, it is indicated for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. The efficacy of Verzenio has been demonstrated in multiple clinical trials. In these studies, Verzenio, often in combination with an aromatase inhibitor or fulvestrant, has been shown to significantly improve progression-free survival compared to standard endocrine therapy alone. Additionally, in certain patient populations, Verzenio has also been associated with an improvement in overall survival.
Verzenio works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), which are proteins that play a role in cell division. By blocking these proteins, Verzenio helps to prevent the proliferation of cancer cells. This mechanism of action is particularly effective in HR+ breast cancer, where estrogen plays a crucial role in cancer cell growth. When used in the appropriate patient population, Verzenio has been a valuable addition to the treatment arsenal against breast cancer, offering a new line of defense for patients with advanced disease.
Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase) Efficacy in Breast Cancer
Phesgo is a combination of two monoclonal antibodies, pertuzumab and trastuzumab, with hyaluronidase, an enzyme that increases tissue permeability, allowing for subcutaneous injection. This combination is approved for use in patients with HER2-positive breast cancer, which is a particularly aggressive form of the disease. Clinical trials have shown that the addition of pertuzumab to trastuzumab and chemotherapy improves progression-free survival and overall survival in the early and metastatic breast cancer settings. The efficacy of this combination has been established in the neoadjuvant (pre-surgery), adjuvant (post-surgery), and metastatic settings.
Phesgo's efficacy is rooted in its dual targeting of the HER2 receptor, which is overexpressed in HER2-positive breast cancer cells. Pertuzumab and trastuzumab bind to different regions of the HER2 receptor, leading to a more comprehensive blockade and preventing the receptor from sending growth signals to the cancer cells. This complementary action results in a more effective treatment against HER2-positive tumors. The introduction of Phesgo as a fixed-dose combination allows for a more convenient administration route, potentially improving patient adherence and quality of life without compromising efficacy.
Regulatory Agency Approvals
Verzenio/Verzenios
Phesgo
Access Verzenio/Verzenios or Phesgo today
If Verzenio/Verzenios or Phesgo are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us